Adherence to Bronchiolitis Guidelines Cuts LOS, Costs

Share this content:
Adherence to Bronchiolitis Guidelines Cuts LOS, Costs
Adherence to Bronchiolitis Guidelines Cuts LOS, Costs

THURSDAY, Feb. 9, 2017 (HealthDay News) -- Adherence to bronchiolitis clinical pathway recommendations is associated with reduced length of stay (LOS) and costs, according to a study published online Feb. 9 in Pediatrics.

Mersine A. Bryan, M.D., from the University of Washington in Seattle, and colleagues conducted a retrospective cohort study involving 267 patients ≤24 months old diagnosed with bronchiolitis. Using a standardized scoring system, the authors assessed clinical pathway adherence for 18 quality measures obtained by medical record review. They classified level of adherence into low, middle, and high tertiles, and examined the correlation between adherence tertile and LOS and costs.

The researchers found that the mean adherence scores were 78.8, 95.0, and 89.1 for emergency department, inpatient, and combined emergency department/inpatient, respectively. Cases in the highest versus the lowest adherence tertile had significantly shorter LOS (emergency department, 90 versus 140 minutes; inpatient, 3.1 versus 3.8 days). Cases in the highest adherence tertile had significantly lower costs (emergency department, −$84; total, −$1,296). The odds of admission were lower for emergency department cases in the highest tertile (odds ratio, 0.38). There was no difference in readmission based on tertile.

"This study illustrates the importance of clinician adherence to specific pathway care processes," the authors write. "By improving adherence to evidence-based recommendations within a clinical pathway, we may be able to provide higher-value care by optimizing the quality of bronchiolitis care at lower costs and with shorter LOS."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »